Loading
Editas Medicine, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Hopfield Jessica, was filed 14 May 2024.
Editas Medicine, Inc.: what insiders have been doing
Editas Medicine, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Cambridge, United States, founded in 2013. Its insiders report their share dealings to SEC (Form 4). Between 23 October 2025 and 23 October 2026, 5 insiders published 17 filings.
All open-market trades in the period are sales: 14 sales worth €92k, by 3 insiders, with no purchase on record. At €36k, the sale published on 5 June 2026 by O'Neill Gilmore Neil is the largest of the period (0.0086% of market cap).
For context, the typical company on the same exchange (median of 3,167 companies) published 24 filings over the same period, against 17 filings here. The full history, which starts in 2016, counts 37 purchases against 211 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 40.5 m USD and net income at -160.1 m USD.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
394
Thresholds
n/a
Buy Volume
€4M
37 ops. · all time
Sell Volume
€47M
211 ops. · all time
Who traded when
BuySaleLinda Burkly9 sales
Amy Parison8 sales
Gilmore Neil O'Neill8 sales
Lucera Erick1 sale
Mei Baisong1 sale
Since the insiders bought
- -76.8%Entry US$6.00 · Close at T+365 US$1.39
- -61.6%Entry US$41.63 · Close at T+365 US$16.00
- +141.8%Entry US$15.64 · Close at T+365 US$37.81
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Editas Medicine, Inc. Buy (bullish), based on 10 analysts. Average price target: US$6.10.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.51
Analyst consensus
10 analystsBuy
US$1.00Target US$6.10(+143%)US$15.00
Income statement
RevenueUS$40.5M
EBITDA-US$148.6M-367% margin
Net income-US$160.1M-157.3% margin
Valuation
PER (forward)-3.3x
P/Book3.7x
Beta2.00
Balance sheet & cash
Market capUS$385.5M
Total debtUS$18.1M
Free Cash Flow-US$165.8M
Debt / Equity15%
Profitability & ownership
ROE-118.8%
ROA-23.3%
% insiders0.2%
% institutions79.4%
Last declaration on 4 September 2026
Declarations394 total
453 shares@ US$3.03720.0003% mcap13.7% of flowCommon StockSEC:0002063082-26-000006:0
5,124 shares@ US$3.03720.0037% mcap4.9% of flowCommon StockSEC:0001742084-26-000003:0
709 shares@ US$3.03720.0005% mcap1.7% of flowCommon StockSEC:0001985604-26-000003:0
700 shares@ US$3.280.0005% mcap1.8% of flowCommon StockSEC144:0001650664-26-000085
5,100 shares@ US$3.280.0040% mcap5.3% of flowCommon StockSEC144:0001650664-26-000087
678 shares@ US$2.580.0004% mcap17.5% of flowCommon StockSEC:0002063082-26-000003:0
4,928 shares@ US$2.670.0032% mcap10.4% of flowCommon StockSEC:0001650664-26-000076:0
5,500 shares@ US$2.880.0038% mcap12.5% of flowCommon StockSEC144:0001650664-26-000074
731 shares@ US$2.70110.0004% mcap1.5% of flowCommon StockSEC:0001650664-26-000055:0
15,380 shares@ US$2.70110.0086% mcap13.1% of flowCommon StockSEC:0001650664-26-000056:0
464 shares@ US$2.7010.0003% mcap12.5% of flowCommon StockSEC:0001650664-26-000057:0
5,394 shares@ US$2.01973.4% of flowCommon StockSEC:0001650664-26-000009:0
749 shares@ US$2.01961.2% of flowCommon StockSEC:0001650664-26-000006:0
474 shares@ US$2.029.5% of flowCommon StockSEC:0001650664-26-000007:0
713 shares@ US$2.15311.2% of flowCommon StockSEC:0001650664-25-000163:0
5,603 shares@ US$2.15313.8% of flowCommon StockSEC:0001650664-25-000162:0
461 shares@ US$2.15319.9% of flowCommon StockSEC:0001650664-25-000161:0
710 shares@ US$2.59611.4% of flowCommon StockSEC:0001650664-25-000143:0
458 shares@ US$2.596111.8% of flowCommon StockSEC:0001650664-25-000142:0
5,592 shares@ US$2.59614.6% of flowCommon StockSEC:0001650664-25-000141:0
679 shares@ US$2.5817.3% of flowCommon StockSEC:0001650664-25-000118:0
5,121 shares@ US$2.491110.0% of flowCommon StockSEC:0001650664-25-000113:0
446 shares@ US$1.7247.8% of flowCommon StockSEC:0001650664-25-000093:0
726 shares@ US$1.72431.0% of flowCommon StockSEC:0001650664-25-000091:0
15,192 shares@ US$1.72438.4% of flowCommon StockSEC:0001650664-25-000089:0
25 of 394 declarations
About Editas Medicine, Inc.
Editas Medicine, Inc. is a U.S.-based biotechnology company listed on the NASDAQ in the United States. Headquartered in Cambridge, Massachusetts, with an operational site in Boulder, Colorado, the company is positioned in the highly innovative and highly volatile gene-editing segment. Founded in 2013 under the original name Gengine, Inc., it later adopted the Editas Medicine name that same year. The company’s identity is closely tied to CRISPR science, with a focus on translating CRISPR/Cas9 and CRISPR/Cas12a genome-editing systems into therapeutic programs. ([editasmedicine.com](https://www.editasmedicine.com/about/?utm_source=openai))
Editas is still best described as a clinical-stage, pre-commercial biotech rather than a revenue-generating pharmaceutical business. Its value proposition depends on scientific execution, regulatory milestones, and eventual commercialization, not on current product sales. The company’s pipeline is centered on transformative medicines for serious diseases with limited treatment options. Its lead in vivo candidate is EDIT-401, designed to treat hyperlipidemia, while EDIT-301 is an ex vivo gene-editing program being developed for hematologic diseases such as sickle cell disease. In earlier phases of the company’s development, Editas also advanced EDIT-101 in ophthalmology, underscoring the breadth of its platform approach. ([editasmedicine.com](https://www.editasmedicine.com/about/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Editas operates in a field characterized by intense R&D competition, high technical barriers, and substantial clinical and regulatory risk. Its differentiation rests on deep CRISPR expertise and an increasing strategic emphasis on in vivo gene editing. Management has highlighted encouraging preclinical evidence for EDIT-401, including strong LDL-C reduction in non-human primates, which supports the program’s potential as a first-in-class or best-in-class contender in a large cardiometabolic market. ([ir.editasmedicine.com](https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2026-results-and?utm_source=openai))
Recent developments have been important. In the first quarter of 2026, Editas said it remained on track to file an IND or CTA for EDIT-401 by mid-2026 and expects initial in-human proof-of-concept data by year-end 2026. The company also presented new preclinical EDIT-401 data at scientific meetings in spring 2026. In addition, Editas reported a favorable procedural development in its CRISPR patent dispute, with the U.S. Patent and Trademark Office reaffirming a prior Broad Institute victory in the interference proceeding involving CRISPR/Cas9 rights. For investors, Editas is therefore a speculative biotechnology name with meaningful upside optionality, but one that remains dependent on clinical progress, regulatory execution, and intellectual-property outcomes. ([ir.editasmedicine.com](https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2026-results-and?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
